AZN - Spark Newswire

1 minute read

Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina

Today, 5:56 PM

Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close at $100.79 on Friday.

AMZN

2 minute read

AstraZeneca Announced Enhertu Recommended for EU Approval in Gastric Cancer

By Charles Gross

Today, 5:56 PM

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

AZN

1 minute read

Biden Administration Official Says U.S. Will Renew Covid-19 Public Health Emergency Declaration In January

By Benzinga Newsdesk

Today, 5:56 PM

- Reuters Nov 11 - The United States in January will extend the COVID-19 pandemic status as a public health emergency, allowing millions of Americans to keep getting free tests, vaccines and treatments until at

AZN

1 minute read

Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows

By Vandana Singh

Today, 5:56 PM

According to a report published in Nature Medicine, COVID-19-reinfected patients had a more than doubled risk of death and a…

AZN

3 minute read

FDA
News

AstraZeneca’s Imfinzi (Durvalumab) In Combination With Imjudo (Tremelimumab) Plus Platinum-based Chemotherapy Has Been Approved By The Us Fda For The Treatment Of Adult Patients With Stage Iv (Metastatic) Non-small Cell Lung Cancer

By Charles Gross

Today, 5:56 PM

AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

AZN

1 minute read

SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78

By Benzinga Newsdesk

Today, 5:56 PM

SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $75 to $78.

AZN

3 minute read

Nasdaq, S&P 500 Futures Show Cautious Optimism Ahead Of October Inflation Print — Tesla, Rivian, Apple, AstraZeneca In Focus

By Shanthi Rexaline

Today, 5:56 PM

The U.S.

AAPL

1 minute read

AstraZeneca Q3 Adj EPS $1.67 Beats $0.72 Estimate, Sales $10.98B Beat $10.91B Estimate

By Benzinga Newsdesk

Today, 5:56 PM

AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $0.72 by 131.94 percent. This is a 56.07 percent increase over earnings of $1.07 per share from the

AZN